1. End-of-Life Delirium: Issues Regarding Recognition, Optimal Management, and the Role of Sedation in the Dying Phase 
Shirley H. Bush, MBBS, MRCGP, FAChPM, Maeve M. Leonard, MB, MRCPsych, MD, Meera Agar, MBBS, FRACP, Juliet A. Spiller, MBChB, MRCPEd, Annmarie Hosie, RN, PhD(C), David Kenneth Wright, RN, PhD, CHPCN(C), David J. Meagher, MD, PhD, MRCPsych, David C. Currow, BMed, MPH, FRACP, Eduardo Bruera, MD, Peter G. Lawlor, MB, FRCPI, MMedSc 
Journal of Pain and Symptom Management 
Volume 48, Issue 2, Pages (August 2014)
DOI: /j.jpainsymman
Copyright © 2014 American Academy of Hospice and Palliative Medicine Terms and Conditions

2. Fig. 1
End-of-life delirium: framework for clinical decision-making and designation of nonreversible and refractory delirium outcomes. *Nonsedating typical or atypical antipsychotic; †add rescue dose of benzodiazepine or change to sedating antipsychotic to specifically achieve mild-to-moderate levels of sedation as a goal; ‡includes other nonpharmacologic approaches.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2014 American Academy of Hospice and Palliative Medicine Terms and Conditions